Arrivent Biopharma, INC

ArriVent BioPharma announces a $250 million at-the-market offering program through a prospectus supplement filed on May 11, 2026.

ArriVent BioPharma reported Q1 2026 results, highlighting clinical advancements for firmonertinib and ARR-002, with cash reserves projected to fund operations into late 2027.

ArriVent BioPharma announced plans to present two preclinical posters on its EGFR inhibitor firmonertinib and novel dual-target ADC ARR-002 at the 2026 AACR Annual Meeting.

ArriVent BioPharma announced its full-year 2025 financial results, reporting a significant increase in net loss and R&D expenses, while highlighting key clinical advancements and a cash runway into Q3 2027.

ArriVent BioPharma announced its third quarter 2025 financial results, highlighting significant clinical progress for firmonertinib in NSCLC and its ADC pipeline, alongside a strong cash position.

ArriVent BioPharma presented positive final data from its global Phase 1b study of firmonertinib monotherapy in EGFR PACC mutant non-small cell lung cancer.

ArriVent BioPharma reports a reduced net loss for Q1 2026 compared to the prior year, with significant cash reserves bolstering its clinical-stage operations and drug development pipeline.

ArriVent BioPharma reports increased R&D expenses and net losses in Q3 2025, driven by clinical trials and new collaborations, while maintaining a strong cash position.

ArriVent BioPharma reported increased Q2 losses but highlighted positive firmonertinib clinical data, new oncology licenses, and a recent $81.1 million capital raise.

ArriVent BioPharma's Q1 2025 shows a significant increase in research and development expenses, driven by new collaborations and continued development of firmonertinib.

ArriVent BioPharma's third quarter 2024 report highlights increased R&D spending, a net loss, and a strong cash position following its IPO.

ArriVent BioPharma reports a net loss of $39.3 million for the first six months of 2024, alongside updates on clinical trials and collaborations.

ArriVent BioPharma, a clinical-stage biopharmaceutical company, reported significant operating losses for fiscal year 2025 while advancing its lead oncology candidates, firmonertinib and ARR-217, through pivotal clinical trials and strategic collaborations.

ArriVent BioPharma details its 2024 financial performance and provides updates on the clinical development of firmonertinib and its ADC collaborations.

ArriVent BioPharma's 10-K filing outlines the company's registered securities, financial status, and ongoing clinical trials, particularly for their lead drug candidate, furmonertinib.

ArriVent BioPharma's Chief Operating Officer, Robin LaChapelle, was granted 130,000 stock options with an exercise price of $22.67, vesting over four years.

ArriVent BioPharma's President of R&D, Stuart Lutzker, was granted 150,000 stock options with an exercise price of $22.67, vesting over four years.

ArriVent BioPharma's Chief Financial Officer, Winston Kung, was granted 140,000 stock options with an exercise price of $22.67, vesting over four years.

ArriVent BioPharma's President and CEO, Zhengbin Yao, was granted 550,000 stock options with an exercise price of $22.67, vesting over four years.

ArriVent BioPharma's General Counsel, James Paul Kastenmayer, received a grant of 130,000 stock options with a ten-year term and a four-year vesting schedule.

Hillhouse Investment Management and HHLR Advisors reported the sale of over 555,000 ArriVent BioPharma common shares for $23.37 each.

ArriVent BioPharma announces its 2025 Annual Meeting and provides details on voting procedures and proposals.

ArriVent BioPharma announces its 2025 annual meeting of stockholders to be held virtually on June 18, 2025, with key proposals including the election of two directors and ratification of PricewaterhouseCoopers LLP as the independent auditor.

ArriVent BioPharma is registering an additional 1,597,223 shares of common stock following its initial public offering.

ArriVent BioPharma is moving forward with its IPO, offering 8,333,333 shares of common stock with an estimated price range of $17.00 to $19.00 per share.

ArriVent BioPharma amends its S-1 filing for an initial public offering of 8.3 million shares, aiming to fund furmonertinib development and pipeline expansion.

OrbiMed Advisors and affiliated entities reported a decrease in their beneficial ownership of ArriVent BioPharma, Inc. common stock to 7.5% due to an increase in the issuer's outstanding shares.

BlackRock, Inc. has filed a Schedule 13G, reporting beneficial ownership of 3,182,080 shares, representing 6.8% of the outstanding common stock of Arrivent Biopharma Inc.

FMR LLC has reported beneficial ownership of 6.8% of Arrivent Biopharma Inc.'s common stock as of March 31, 2026.

Sofinnova Venture Partners XI and its affiliates have filed an amended Schedule 13G, disclosing a 4.1% beneficial ownership in ArriVent Biopharma, Inc. as of December 31, 2025.

Hillhouse Investment Management, Ltd. has reported a 9.5% beneficial ownership stake in ArriVent BioPharma, Inc., holding 3,929,117 shares of common stock.

The Vanguard Group reported a beneficial ownership of 4.52% in ArriVent Biopharma Inc. as of December 31, 2025, following an internal realignment.

BlackRock, Inc. has reported a 5.6% beneficial ownership stake in Arrivent Biopharma Inc., holding over 2.3 million common shares as of December 31, 2025.